First Tracks Biotherapeutics Stock Climbs Nearly 8% as Celiac Drug Hopes Push Shares Up 160% in a Year
First Tracks Biotherapeutics Inc. (TRAX) shares rose 8% to $53.57, extending a 160% year-to-date gain. The rally follows positive Phase 1b trial results for its celiac disease drug, ANB033, which showed significant protection against intestinal damage. The company has no new updates but plans late-stage development in 2027. TRAX is valued at $2.2B and reported a Q3 net loss of $31.4M.
How this was made

The 30-second read
Why it matters
The short‑term price move reflects investor enthusiasm for early data, but the lack of new information suggests limited actionable insight.
Market read
The story is a recap of already‑public trial results, offering minimal new trading impetus beyond a modest intraday rally.
What to watch
Fast Track designation may accelerate regulatory timeline, but the small Phase 1b size limits confidence.
Background
First Tracks Biotherapeutics (TRAX) is a clinical‑stage biotech focused on antibody therapies for autoimmune diseases. The article recaps Phase 1b celiac data released earlier in October and notes a recent 8% intraday rally.
Ticker impact
Shares rose ~8% on Tuesday as investors reacted to early Phase 1b celiac data that was first disclosed earlier in the month.
modest upside as the market may add a few points on optimism, but limited upside unless later data exceed expectations
The trial results were released on Oct. 12 and have been discussed for weeks; the move is a short‑term reaction rather than a new catalyst.
Market effects
Positive signal for the broader autoimmune biotech sector, but no immediate shift in competitive dynamics.
Limited to U.S. biotech investors; no broader regional effect.
Minor, confined to niche biotech investors.
Counterpoint
The data are already priced in; a later trial failure could trigger a sharp pull‑back.
Key entities
- companyFirst Tracks Biotherapeutics Inc.
Clinical‑stage biotech developing ANB033 for celiac disease.
- drugANB033
Experimental antibody targeting CD122 for celiac disease.
